Sign up to save your podcasts
Or
Share 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
View all episodes
By STAT
4.5
309309 ratings
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
More shows like The Readout Loud
View all
Planet Money
30,678 Listeners
Odd Lots
1,896 Listeners
What the Health? From KFF Health News
499 Listeners
The Indicator from Planet Money
9,513 Listeners
The Journal.
6,086 Listeners
Tradeoffs
394 Listeners
Biotech 2050 Podcast
61 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Dwarkesh Podcast
505 Listeners
Hard Fork
5,473 Listeners
Biotech Hangout
19 Listeners
Ground Truths
48 Listeners
Money Stuff: The Podcast
387 Listeners
The BioCentury Show
12 Listeners